About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Medicine still has many challenges to solve specially on complex diseases were a large number of both, genetic and environmental factors are involved. Among them, neurodegenerative and autoimmune disorders affecting the central nervous system have attracted attention because CNS is difficult to access and to manipulate with classical pharmacological treatments and, in addition, there are no effective curative treatments for these diseases. To address these problems, we have focused our research interests in gene therapy strategies for autoimmune diseases and neurodegenerative disorders specially those associated to aging.
IP: -
IP: Joan Roig Soriano Collaborators: - Funding agency: Fundació Institut de Recerca HUVH Funding: 15000 Reference: VHIR-FIT-2025-005 Duration: 01/07/2025 - 30/06/2026
IP: Joan Roig Soriano Collaborators: Miguel Chillon Rodriguez, Elsa Ibarrola Carrasco, David Ramirez Gomez Funding agency: Fundació Institut de Recerca HUVH Funding: 10000 Reference: VHIR-FIT-24-002 Duration: 13/12/2024 - 12/12/2025
IP: Joan Roig Soriano Collaborators: Miguel Chillon Rodriguez Funding agency: Fundació "La Caixa" Funding: 64450 Reference: CI24-20581 Duration: 15/10/2024 - 14/10/2026
IP: M Mar Mañu Pereira Collaborators: Augusto Cesar Sao Aviles, Patricia González Ruiz, Claire Diot, Miguel Chillon Rodriguez, Simon Schwartz Navarro, Sara Isabel Reidel Funding agency: EUROPEAN COMMISSION Funding: 1252083.33 Reference: ERDERA/EC/HLTH-2023-DISEASE-07-01/2023/MAÑU Duration: 01/09/2024 - 31/08/2031
PhD student: Jon Esandi Jauregui Director/s: Miguel Chillon Rodriguez University: Universitat Autònoma de Barcelona Year: 2024
PhD student: Rebeca Blanch Garcia Director/s: Miguel Chillon Rodriguez University: Universitat Autònoma de Barcelona Year: 2023
PhD student: Joan Roig Soriano, Joan Roig Soriano Director/s: Miguel Chillon Rodriguez University: Universitat Autònoma de Barcelona Year: 2023
PhD student: Angel Edo Salvador Director/s: Miguel Chillon Rodriguez, Xavier Montalban Gairín, Xavier Montalban Gairín University: Year: 2020
PhD student: Marc García Moure Director/s: Miguel Chillon Rodriguez University: Universidad Autònoma de Barcelona Year: 2016
The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.
The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.
This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.
Check the current rates for the services offered by the Gene Therapy at Nervous System research group.
